Biblio Discovery — Demo Discovery Service

4 results for "Mehreen S. Datoo"

Showing 1–4 · 0.55 seconds · RSS

  1. Journal Article Full text

    Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial

    Pedro M. Folegatti; Mustapha Bittaye; Amy Flaxman et al.

    The Lancet Infectious Diseases · 2020 · English · OpenAlex Scopus

    Background Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective…

  2. Journal Article

    Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

    Mehreen S. Datoo; Hamtandi Magloire Natama; Athanase Somé et al.

    The Lancet Infectious Diseases · 2022 · English · OpenAlex Scopus

    BACKGROUND: Malaria is a leading cause of morbidity and mortality worldwide. We previously reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified goal of 75% or greater efficacy over 12 months in the target population of African children. Here, we report the…

  3. Journal Article Full text

    Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial

    Mehreen S. Datoo; Hamtandi Magloire Natama; Athanase Somé et al.

    The Lancet · 2021 · English · OpenAlex

    BACKGROUND: Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new…

  4. Journal Article Full text

    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

    Mehreen S. Datoo; Alassane Dicko; Halidou Tinto et al.

    The Lancet · 2024 · English · OpenAlex

    BACKGROUND: Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four…